ClinicalTrials.Veeva

Menu
C

Clinica Universidad de Navarra | Sede Madrid - Hematology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lenalidomide
Carboplatin
Platinum
Daratumumab
Nivolumab
Pembrolizumab
Dexamethasone
Cemiplimab
Abemaciclib
Cisplatin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

51 of 75 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during...

Enrolling
Marginal Zone Lymphoma
Follicular Lymphoma
Biological: rituximab
Biological: EO2463

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors.Estimate the maximum tolerated dose...

Active, not recruiting
KRAS p.G12C Mutant Advanced Solid Tumors
Drug: Anti PD-1/L1
Drug: sotorasib

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on v...

Enrolling
Pulmonary Embolism
Venous Thromboembolism
Biological: Abelacimab
Drug: Apixaban

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembol...

Enrolling
Pulmonary Embolism
Venous Thromboembolism
Biological: Abelacimab
Drug: Dalteparin

This is an open-label, non-randomized, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of MCLA-145 in adult patients wi...

Active, not recruiting
Advanced Cancer
Solid Tumor, Adult
Drug: MCLA-145
Drug: Pembrolizumab (Keytruda)

This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advan...

Active, not recruiting
Solid Tumor
Colorectal Adenocarcinoma
Drug: Nivolumab and Nal-IRI/5-FU/LV - Expansion
Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
Locations recently updated

The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Aut...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab
Locations recently updated

This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other place...

Enrolling
Ovarian Neoplasms
Carcinoma, Non-Small-Cell Lung
Drug: disitamab vedotin

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab an...

Enrolling
Carcinoma, Hepatocellular
Other: Placebo
Drug: Relatlimab

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Olezarsen
Drug: Placebo

This is a Phase 2, controlled, randomised, parallel assignment, open label, multicentre study to evaluate efficacy and safety of a single intraperito...

Enrolling
Ovarian Cancer
Peritoneal Carcinomatosis
Drug: Radspherin
Locations recently updated

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or me...

Enrolling
Locally Advanced Solid Tumors
Primary CNS Tumors
Drug: Oral repotrectinib (TPX-0005)

The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearr...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Cisplatin
Drug: Selpercatinib

The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with...

Active, not recruiting
Medullary Thyroid Cancer
Drug: Selpercatinib
Drug: Vandetanib

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with...

Enrolling
Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma
Drug: Rituximab
Drug: Lenalidomide

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous S...

Active, not recruiting
Cutaneous Squamous Cell Carcinoma
Drug: INCB099280

This study has two parts: Part 1 and Part 2. The purpose of this study in Part 1, Dose Escalation Part is to determine the maximum tolerated dose (MT...

Enrolling
Advanced Solid Tumors
Drug: Debio 0123

This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multip...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Nirogacestat

Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-c...

Enrolling
Multiple Myeloma
Drug: Daratumumab
Drug: Dexamethasone

Trial sponsors

Pfizer logo
U
Regeneron Pharmaceuticals logo
Debiopharm logo
Seagen logo
A
Daiichi Sankyo logo
ImmunoGen logo
Loxo Oncology logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems